| 1. |
- Cwikiel, Wojciech, et al.
(författare)
-
Disappearance of esophageal carcinoma after stenting combined with endoscopic laser therapy
- 1995
-
Ingår i: Cardiovascular and Interventional Radiology. - 0174-1551. ; 18:4, s. 247-250
-
Tidskriftsartikel (refereegranskat)abstract
- A 92-year-old man with dysphagia secondary to squamous cell carcinoma of the esophagus was palliated repeatedly with endoscopic laser therapy and insertion of esophageal stents. During the treatment period of 32 months, the patient could be fed perorally while ingrowth of tumor, development of new stenoses at the edges of the stents, and breakage of one stent were encountered. A tracheoesophageal fistula developed at the upper edge of the first stent. The patient died from aspiration pneumonia. At autopsy, no cancer cells were found in the esophagus. Combined endoscopic laser treatment and stent therapy may keep a patient free from dysphagia during a long period of time and also may result in the complete disappearance of tumor growth in the esophagus.
|
|
| 2. |
- Friberg, Britt, et al.
(författare)
-
Endometrial destruction by thermal coagulation : Evaluation of a new form of treatment for menorrhagia
- 1998
-
Ingår i: Gynaecological Endoscopy. - : Wiley. - 0962-1091 .- 1365-2508. ; 7:2, s. 73-78
-
Tidskriftsartikel (refereegranskat)abstract
- Objective. To report the first clinical evaluation of a new balloon endometrial, thermal destruction system Cavaterm®, for outpatient treatment of menorrhagia. Design. To elucidate possible technical problems during treatment, to evaluate how the patients tolerated the treatment and to judge which patients were suitable for this form of treatment. Main outcome measures. Measurements of bleeding volumes in pads and tampons before and after treatment were performed as well as subjective evaluation by bleeding charts. Patients also estimated their degree of satisfaction. Setting. Gynaecology department at a university hospital. Subjects. 36 patients under 52 pears of age with menorrhagia, without suspicion of intracavitary pathology including malignancy. Results. No procedure-related complications occurred. The patients tolerated the treatment well. There was a significant reduction in measured bleeding volumes in pads and tampons, collected during one menstruation, 2-7 months after treatment compared with measurements before treatment. Four patients subsequently underwent hysterectomy and should not have been included in the study (two with pedunculated myoma and one with a septum; the fourth showed premalignant endometrial changes in the curettage preceding the treatment). At 18-28-month follow up, 29 of the suitable patients (91%) reported a significant reduction in bleeding and another three patients reported reduced but still profuse bleeding compared with pretreatment; 88% (28/32) rated the treatment results as excellent, and a further 9% (3/32) as good. Conclusions. We found the Cavaterm® system for endometrial destruction to be safe, efficient and easy to use.
|
|
| 3. |
- Löfberg, Robert, et al.
(författare)
-
Oral budesonide versus prednisolone in patients with extensive and left sided ulcerative colitis
- 1996
-
Ingår i: Gastroenterology. - : Elsevier BV. - 1528-0012 .- 0016-5085. ; 110:6, s. 1713-1718
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND & AIMS: Systemic glucocorticosteroids (GCSs) have proven efficacy in active ulcerative colitis but cause undesired systemic side effects. Therefore, new GCSs with high topical activity and a high rate of metabolism may be of clinical value in this condition. The aim of this study was to explore the efficacy and safety of the topically acting GCS budesonide in an oral controlled-release formulation in extensive or left-sided, mild to moderately active ulcerative colitis. METHODS: A 9-week, randomized, double-blind, controlled trial was performed, and treatments with 10 mg budesonide or 40 mg prednisolone daily, both gradually tapered, were compared. Endoscopic improvement and effect on endogenous plasma cortisol were assessed. RESULTS: Thirty-four patients were administered budesonide, and 38 patients were administered prednisolone. Mean endoscopic scores improved significantly in both groups but without difference between the groups. Five patients in the budesonide group and 7 patients in the prednisolone group deteriorated and were withdrawn from the study. Morning plasma cortisol levels were suppressed in the prednisolone group (entry, 449 nmol/L; 2 weeks, 116 nmol/L; 4 weeks, 195 nmol/L) but were unchanged in the budesonide group. CONCLUSIONS: The GCS budesonide administered in an oral controlled-release formulation seems to give an overall treatment result in active ulcerative colitis approaching that of prednisolone but without suppression of plasma cortisol levels. This concept merits further evaluation.
|
|
